Methods for determining the PK parameters of albudabs™ and of long serum half-life drugs made using the albudab™ technology

Methods in Molecular Biology

Volumn 911, Issue , 2012, Pages 457-473

  Rycroft, Daniel ^a   Holt, Lucy J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

AlbudAb ; Antibody fragment; dAb ; Domain Antibody; Half life; PK; Therapeutic

Indexed keywords

ALBUDAB; ALBUMIN BINDING DOMAIN ANTIBODY; ANTIBODY; NANOBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; EXPERIMENTAL RABBIT; NONHUMAN; PHAGE DISPLAY; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT;

EID: 84934442500     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-968-6_28     Document Type: Article

References (14)

1. St Onge EL, Miller SA (2010) Albiglutide; a new GLP-1 analogue for the treatment of type 2 diabetes. Expert Opin Biol Ther 10:801-806
2. Lee H (2003) Population pharmacokinetic and pharmacodynalic modelling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348-365
3. Syed S et al (1997) Potent antithrombin activity and delayed clearance from the circulation characterise recombinant hirudin genetically fused to albumin. Blood 89:3243-3252
4. Osborn BL et al (2002) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303:540-548
5. Mohler KM et al (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151: 1548-1561
6. Pasut G, Veronese FM (2009) PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today 45:687-695
7. Holt LJ et al (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 21:283-288
8. Walker A et al (2010) Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel 23:271-278
9. Peters T Jr (1985) Serum albumin. Adv Protein Chem 37:161-245
10. Ward ES et al (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Eschericia Coli. Nature 341:544-546
11. Rhyne PW et al (2009) Electrochemiluminescence in bioanalysis. Bioanalysis 1:919-935
12. Miao W (2008) Electrogenerated chemilumi-nescence and its biorelated applications. Chem Rev 108:2506-2553
13. DiStefano III (1982) Non-compartmental vs compartmental analysis: some bases for choice. Am J Physiol 243:R1-R6
14. Jacquez JA, Simon SP (1993) Qualitative theory of compartmental analysis. SIAM Rev 35:43-79